Carna Biosciences, Inc. (TYO:4572)
Japan
· Delayed Price · Currency is JPY 312.00
-23.00 (-6.87%)
Jun 19, 2025, 3:30 PM JST
Carna Biosciences Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 1,529 | 2,108 | 2,889 | 3,379 | 3,817 | 4,299 | Upgrade
|
| Cash & Short-Term Investments | 1,529 | 2,108 | 2,889 | 3,379 | 3,817 | 4,299 | Upgrade
|
| Cash Growth | -51.59% | -27.03% | -14.50% | -11.47% | -11.21% | -12.53% | Upgrade
|
| Receivables | 83.27 | 87 | 788 | 182 | 1,243 | 129 | Upgrade
|
| Inventory | 160.85 | 154 | 140 | 118 | 110 | 104 | Upgrade
|
| Other Current Assets | 352.71 | 388 | 374 | 425 | 148 | 176 | Upgrade
|
| Total Current Assets | 2,126 | 2,737 | 4,191 | 4,104 | 5,318 | 4,708 | Upgrade
|
| Property, Plant & Equipment | - | - | 105 | 100 | 51 | 53 | Upgrade
|
| Long-Term Investments | 46.21 | 34 | 51 | 59 | 59 | 70 | Upgrade
|
| Other Intangible Assets | - | - | 1 | 1 | 2 | 3 | Upgrade
|
| Other Long-Term Assets | 0 | 1 | 1 | 2 | 2 | 1 | Upgrade
|
| Total Assets | 2,172 | 2,772 | 4,349 | 4,266 | 5,432 | 4,835 | Upgrade
|
| Accounts Payable | - | 2 | 1 | 1 | 2 | 1 | Upgrade
|
| Current Portion of Long-Term Debt | 19.99 | 19 | 120 | 151 | 239 | 189 | Upgrade
|
| Current Portion of Leases | - | 8 | 6 | - | - | - | Upgrade
|
| Current Income Taxes Payable | 3.48 | 180 | 218 | 265 | 332 | 344 | Upgrade
|
| Current Unearned Revenue | - | - | - | - | 177 | 169 | Upgrade
|
| Other Current Liabilities | 127.32 | 13 | 30 | 19 | 24 | 24 | Upgrade
|
| Total Current Liabilities | 150.79 | 222 | 375 | 436 | 774 | 727 | Upgrade
|
| Long-Term Debt | 3.41 | 8 | 28 | 148 | 300 | 239 | Upgrade
|
| Long-Term Leases | - | 24 | 28 | - | - | - | Upgrade
|
| Other Long-Term Liabilities | 62.19 | 44 | 42 | 42 | 45 | 45 | Upgrade
|
| Total Liabilities | 216.39 | 298 | 473 | 626 | 1,119 | 1,011 | Upgrade
|
| Common Stock | 2,448 | 2,447 | 2,076 | 1,382 | 1,056 | 558 | Upgrade
|
| Additional Paid-In Capital | 6,199 | 6,198 | 5,827 | 5,133 | 4,808 | 4,310 | Upgrade
|
| Retained Earnings | -6,753 | -6,253 | -4,075 | -2,922 | -1,572 | -1,038 | Upgrade
|
| Comprehensive Income & Other | 62.61 | 82 | 48 | 47 | 21 | -6 | Upgrade
|
| Shareholders' Equity | 1,956 | 2,474 | 3,876 | 3,640 | 4,313 | 3,824 | Upgrade
|
| Total Liabilities & Equity | 2,172 | 2,772 | 4,349 | 4,266 | 5,432 | 4,835 | Upgrade
|
| Total Debt | 23.4 | 59 | 182 | 299 | 539 | 428 | Upgrade
|
| Net Cash (Debt) | 1,506 | 2,049 | 2,707 | 3,080 | 3,278 | 3,871 | Upgrade
|
| Net Cash Growth | -50.48% | -24.31% | -12.11% | -6.04% | -15.32% | -7.57% | Upgrade
|
| Net Cash Per Share | 81.85 | 114.41 | 161.13 | 226.18 | 258.20 | 314.74 | Upgrade
|
| Filing Date Shares Outstanding | 19.1 | 19.1 | 17.14 | 16.34 | 13.48 | 12.4 | Upgrade
|
| Total Common Shares Outstanding | 19.1 | 19.1 | 17.14 | 14.21 | 13.31 | 12.4 | Upgrade
|
| Working Capital | 1,975 | 2,515 | 3,816 | 3,668 | 4,544 | 3,981 | Upgrade
|
| Book Value Per Share | 102.43 | 129.55 | 226.07 | 256.14 | 324.08 | 308.34 | Upgrade
|
| Tangible Book Value | 1,956 | 2,474 | 3,875 | 3,639 | 4,311 | 3,821 | Upgrade
|
| Tangible Book Value Per Share | 102.43 | 129.55 | 226.02 | 256.07 | 323.93 | 308.10 | Upgrade
|
| Order Backlog | - | 13.09 | 39.76 | 58.12 | 257.29 | 214.93 | Upgrade
|
Updated Feb 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.